Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
This study aimed to determine the efficacy and tolerability of adding quetiapine to a serotonin reuptake inhibitor in treatment-resistant obsessive-compulsive disorder (OCD). Twenty-one adult treatment-resistant OCD patients were randomized to 16 weeks of augmentation with either quetiapine (n = 11) or placebo (n = 10). Patients with significant comorbidities, including tic-spectrum disorders, were not included. The treatment was well tolerated, with only one premature dropout in each treatment-group. The primary analysis showed that individuals in the quetiapine-treated group showed a 14% mean improvement in baseline Yale-Brown Obsessive-Compulsive Scale scores at study endpoint compared with a 6% improvement in those treated with placebo, but this difference did not reach statistical significance (F<1). Three patients treated with quetiapine met criteria for clinical response, compared to one patient who was treated with placebo. Larger studies are needed to explore the efficacy of second generation antipsychotics, such as quetiapine, when used as adjunct treatment in resistant OCD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, an estimated 40–60% of patients does not respond to this treatment and require additional treatment with atypical antipsychotics, which affects both the serotonergic and dopaminergic system (Denys et al., 2004a; Fineberg et al., 2005).”
From Response Inhibition and Interference Control in Obsessive–Compulsive Spectrum Disorders (2014) · cites this paper as Fineberg et al., 2005
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The yale global tic severity scale: initial testing of a clinician-rated scale of tic severity
LECKMAN, J. F., RIDDLE, M. A., HARDIN, M. T., ORT, S. I., SWARTZ, K. L., STEVENSON, J., & COHEN, D. J. (1989) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-198907000-00015 · Cited by 2,146
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571 · cited 2×
“Although McDougle et al. (2000) did not find a statistical association between tic disorder and treatment response, only one of the studies that reported a positive effect for adjunctive antipsychotics in OCD (Denys et al., 2004) specifically excluded comorbid tics, and distinguishing between…”
BackgroundResultTreatment non-response in OCD: methodological issues and operational definitions
Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti, D., Pato, M., Stein, D., Zohar, J., & International Treatment Refractory OCD Consortium (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002900 · Cited by 416
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Self-citationBystritsky, A., Ackerman, D. L., Rosen, R. M., Vapnik, T., Gorbis, E., Maidment, K. M., & Saxena, S. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0418 · Cited by 220 · cited 2×
“Moreover, positive studies of antipsychotic agents in similar sized samples of resistant OCD cases have been reported (Bystritsky et al., 2004).”
BackgroundEvidence-based pharmacotherapy of obsessive–compulsive disorder
Fineberg, N. A., & Gale, T. M. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004675 · Cited by 211
Self-citationHollander, E., Rossi, N. B., Sood, E., & Pallanti, S. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003730 · Cited by 197 · cited 1×
“Previous trials have also been of relatively short duration (4–8 weeks), which might explain the failure of some of them to demonstrate efficacy (e.g. Hollander et al., 2003).”
ResultShapira, N. A., Ward, H. E., MANDOKI, M. W., Murphy, T. K., Yang, M. C. K., Blier, P., & Goodman, W. K. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.11.010 · Cited by 154
Atmaca, M., Kuloglu, M., Tezcan, E., & Gecici, O. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200205000-00004 · Cited by 149
Research works printed but not linked: 7
- Barnes, 1989, Br J Psychiatry, 154, 72???676
- Denys, 2004, J Clin Psychiatry, 65, 1040???1048
- Goodman, 1989, Arch Gen Psychiatry, 46, 1006???1011
- Leon, 1992, Soc Psychiatry Psychiatr Epidemiol, 27, 78???82
- March, 1997, J Clin Psychiatry, 58, 1???72
- McDougle, 1994, Arch Gen Psychiatry, 51, 302???308
- Simpson, 1970, Acta Psychiatr Scand Suppl, 212, S11???S19
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Another option which may be useful as an adjunctive therapy in those with refractory OCD is the atypical antipsychotic quetiapine (Level 1, conflicting) [728,746,747,764-766,768].”
BackgroundBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Probing compulsive and impulsive behaviors, from animal models to endophenotypes: A narrative review
Fineberg, N. A., Potenza, M. N., Chamberlain, S. R., Berlin, H. A., Menzies, L., Bechara, A., Sahakian, B. J., Robbins, T. W., Bullmore, E. T., & Hollander, E. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.185 · Cited by 654
“OCD typically responds to serotonin reuptake inhibitors (SRIs; clomipramine and selective SRIs, SSRIs) and to SSRIs combined with antipsychotic agents (Fineberg et al, 2005).”
BackgroundSelf-citationBloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635
Maher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011) · JAMA · doi:10.1001/jama.2011.1360 · Cited by 558
Metadata
- Authors
- Fineberg, N. A., Sivakumaran, T., Roberts, A., & Gale, T.
- Affiliations
- Queen Elizabeth II Hospital (GB)
- University of Hertfordshire (GB)
- Corresponding author
- Fineberg, Naomi A.
- Venue
- International Clinical Psychopharmacology
- Published
- 2005-07
- Volume
- 20
- Issue
- 4
- Pages
- 223-226
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2069929468
- Cited by
- 105
- References
- 15
- Citations by year
- 2026: 1 · 2024: 4 · 2023: 2 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 6 · 2017: 3 · 2016: 3 · 2015: 7 · 2014: 8 · 2013: 5 · 2012: 8
- FWCI
- 12.34
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion, cc-by-nc-nd)
- Funders
- AstraZeneca
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- quetiapine, treatment-resistant OCD, serotonin reuptake inhibitors, augmentation therapy, atypical antipsychotics, Yale-Brown Obsessive Compulsive Scale, tolerability, adjunctive therapy
- MeSH terms
- Quetiapine Fumarate, Adult, Dibenzothiazepines, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Placebos, Antipsychotic Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. https://app.cochat.ai/papers/10.1097/00004850-200507000-00005
- The paper
- Fineberg, N. A., Sivakumaran, T., Roberts, A., & Gale, T. (2005). Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200507000-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.